Substudies Onset of lactation: In order to determine if the onset

Substudies Onset of lactation: In order to determine if the onset of lactation is delayed in women with diabetes, we are recruiting a comparison group of 200 women without diabetes. Women are being recruited in

the postnatal wards at the RWH in selleck kinase inhibitor 2014, and followed by telephone at 1–2 weeks postpartum, using identical questions to the DAME interview. Antenatal colostrum: We plan to conduct a biochemical analysis of some excess samples of antenatal colostrum that infants have not required. Supplementary Material Author’s manuscript: Click here to view.(2.1M, pdf) Reviewer comments: Click here to view.(89K, pdf) Acknowledgments The authors are grateful to all the trial sites for their support of the DAME trial. They also thank the women and their babies participating in this trial. Footnotes Contributors: DAF, AMM and KM conceptualised the study, and SJ, LHA, PD, SPW, GO, SMD, RF, CM, AA and LG contributed to study design. DAF, LHA, AMM, KM drafted protocol and

all authors contributed to protocol revision and application of grant. DAF, LHA, AMM developed data collection tools and all authors contributed to refinement, piloting and completion of tools. AMM, KM, LHA, GO, SJ and DAF piloted and refined the intervention. AMM, DAF, AA and CM developed the recruitment processes. DAF, AMM and LHA developed the data collection process. DAF and LHA drafted the trial protocol manuscript, and all authors read and contributed to drafts, and read and approved final manuscript. Funding: This trial is funded by a project grant from the National Health and Medical Council of Australia (no. 1005345). We have also received equipment grants from the National Health and Medical Council of Australia. Competing interests: None. Ethics approval: La Trobe University and participating hospital sites. Provenance and peer review: Not commissioned; externally peer reviewed.
Current prostate cancer treatments can cause major side effects including urinary incontinence, erectile dysfunction and bowel urgency. These

side effects occur due to damage of the (1) neurovascular bundles, (2) urethra including distal urethral smooth muscle sphincter, (3) puboprostatic ligaments and (4) rectum wall. To avoid damage to these structures, several ablative modalities have been introduced with the aim of effective cancer control without jeopardising Cilengitide functional outcomes. Preclinical studies with irreversible electroporation (IRE), a novel ablative modality, demonstrated an advantage over other focal therapies by effective ablation of tumour tissue, while sparing surrounding tissue and vital structures such as blood vessels, urethra and nerve bundles.1–3 It has been suggested that the potential of IRE to spare essential structures may help to reduce or even avoid side effects in the focal treatment of prostate cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>